Veklury is an antiviral medicine used to treat coronavirus disease 2019 (COVID-19). It is used in adults and adolescents (from 12 years of age and weighing at least 40 kilograms) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at the start of treatment). The medicine can also be used in adults who do not require supplemental oxygen and who are at increased risk of developing severe COVID-19.
Veklury contains the active substance remdesivir.
Veklury : EPAR - Medicine overview (PDF/124.65 KB)
First published: 06/07/2020
Last updated: 22/12/2021
Veklury : EPAR – Risk management plan (PDF/1.89 MB)
First published: 22/07/2020
Last updated: 22/12/2021
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
This medicine received a conditional marketing authorisation. This was granted in the interest of public health because the medicine addresses an unmet medical need and the benefit of immediate availability outweighs the risk from less comprehensive data than normally required. For more information, see Conditional marketing authorisation.
Gilead Sciences Ireland UC
|Date of issue of marketing authorisation valid throughout the European Union||
IDA Business & Technology Park
03/02/2022 Veklury - EMEA/H/C/005622 - II/0026/G
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
- Veklury is indicated for the treatment of coronavirus disease 2019 (COVID 19) in: adults and adolescents (aged 12 to less than 18 years and weighing at least 40 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment)
- adults who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 December 202117/12/2021
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 7-10 December 202011/12/2020
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 28 September - 1 October 202002/10/2020